Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,461 to 2,480 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI vs Non-Ellipta MITT: serious adverse events | 114 of 1,545 114 of 1,547 | 0.0 points -1.8 to 1.9 | 3,092 | NCT03467425 INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Postoperative Staphylococcus (S.) Aureus Bloodstream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 90 Days After Spinal Surgery | 14 of 1,544 14 of 1,547 | 0.0 points -0.7 to 0.7 | 3,091 | NCT02388165 Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Any Postoperative S. Aureus Surgical-site Infection (SSI-Superficial, Deep Incisional or Organ/Space) Occurred Within 180 Days After Surgery | 25 of 1,544 23 of 1,547 | 0.1 points -0.8 to 1.0 | 3,091 | NCT02388165 Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Any Postoperative S. Aureus Surgical-site Infection (SSI-Superficial, Deep Incisional or Organ/Space) Occurred Within 90 Days After Surgery | 24 of 1,544 22 of 1,547 | 0.1 points -0.8 to 1.0 | 3,091 | NCT02388165 Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Postoperative S. Aureus Blood Stream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 180 Days After Surgery | 14 of 1,544 14 of 1,547 | 0.0 points -0.7 to 0.7 | 3,091 | NCT02388165 Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation |
| Panitumumab vs Concomitant Administration of Panitumumab and Chemotherapy: serious adverse events | 614 of 1,254 747 of 1,831 | 8.2 points 4.6 to 11.7 | 3,085 | NCT02089737 Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance) |
| Etanercept vs Tocilizumab: serious adverse events | 422 of 1,542 479 of 1,538 | -3.8 points -7.0 to -0.6 | 3,080 | NCT01331837 A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors |
| Experimental vs Placebo: deaths from any cause | 2 of 1,541 1 of 1,536 | 0.1 points -0.3 to 0.4 | 3,077 | NCT05281094 Efficacy and Safety of Two Doses of HIL-214 in Children |
| Experimental vs Placebo: serious adverse events | 169 of 1,541 165 of 1,536 | 0.2 points -2.0 to 2.4 | 3,077 | NCT05281094 Efficacy and Safety of Two Doses of HIL-214 in Children |
| Low-dose CT vs Standard-dose CT: Number of Negative Appendectomies | 22 of 1,535 16 of 1,539 | 0.4 points -0.4 to 1.2 | 3,074 | NCT01925014 Low vs. Standard Dose CT for Appendicitis Trial |
| Low-dose CT vs Standard-dose CT: Number of Appendectomies | 559 of 1,535 601 of 1,539 | -2.6 points -6.1 to 0.8 | 3,074 | NCT01925014 Low vs. Standard Dose CT for Appendicitis Trial |
| Low-dose CT vs Standard-dose CT: Prevalence of Perforated Appendicitis | 182 of 1,535 176 of 1,539 | 0.4 points -1.9 to 2.7 | 3,074 | NCT01925014 Low vs. Standard Dose CT for Appendicitis Trial |
| Low-dose CT vs Standard-dose CT: Prevalence of Non-perforated Appendicitis | 342 of 1,535 388 of 1,539 | -2.9 points -5.9 to 0.1 | 3,074 | NCT01925014 Low vs. Standard Dose CT for Appendicitis Trial |
| Low-dose CT vs Standard-dose CT: Need for Additional Imaging Test(s) | 39 of 1,535 41 of 1,539 | -0.1 points -1.3 to 1.0 | 3,074 | NCT01925014 Low vs. Standard Dose CT for Appendicitis Trial |
| Low-dose CT vs Standard-dose CT: serious adverse events | 43 of 1,535 40 of 1,539 | 0.2 points -1.0 to 1.4 | 3,074 | NCT01925014 Low vs. Standard Dose CT for Appendicitis Trial |
| Patient Directed Standard of Care vs Enhanced Standard of Care: Completion of Pre-test Genetic Counseling From Electronic Health Record | 400 of 1,554 361 of 1,519 | 2.0 points -1.1 to 5.0 | 3,073 | NCT03985852 Broadening the Reach, Impact, and Delivery of Genetic Services |
| Patient Directed Standard of Care vs Enhanced Standard of Care: Completion of Genetic Testing From Electronic Health Record | 191 of 1,554 206 of 1,519 | -1.3 points -3.7 to 1.1 | 3,073 | NCT03985852 Broadening the Reach, Impact, and Delivery of Genetic Services |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants With Statin Addition at 12 Months | 162 of 1,648 151 of 1,423 | -0.8 points -3.0 to 1.4 | 3,071 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Best Practice Clinic-Based Care vs Telehealth Care: deaths from any cause | 42 of 1,648 43 of 1,423 | -0.5 points -1.7 to 0.7 | 3,071 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Group 1: Tamoxifen + Anastrozole Placebo vs Group 2: Anastrazole + Tamoxifen Placebo: serious adverse events | 73 of 1,535 62 of 1,535 | 0.7 points -0.7 to 2.2 | 3,070 | NCT00053898 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy |
Code
curl "https://conductscience.org/api/comparisons/v1?page=124"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=124
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03467425-sae",
"title": "FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI vs Non-Ellipta MITT: serious adverse events",
"summary": "114 of 1545 against 114 of 1547; risk difference 0.0 points, 95% interval -1.8 to 1.9; NCT03467425, INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design",
"record": "/library/comparisons/NCT03467425-sae",
"nct_id": "NCT03467425",
"kind": "serious-adverse-events",
"participants": 3092,
"risk_difference": {
"value": 0.00009539289950483143,
"lower": -0.01842451337196715,
"upper": 0.018618733630048553
},
"group_1": "114 of 1,545",
"group_2": "114 of 1,547",
"difference": "0.0 points",
"interval": "-1.8 to 1.9",
"trial_title": "INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design"
},
{
"id": "NCT02388165-0be3c845",
"title": "Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Postoperative Staphylococcus (S.) Aureus Bloodstream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 90 Days After Spinal Surgery",
"summary": "14 of 1544 against 14 of 1547; risk difference 0.0 points, 95% interval -0.7 to 0.7; NCT02388165, Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation",
"record": "/library/comparisons/NCT02388165-0be3c845",
"nct_id": "NCT02388165",
"kind": "outcome",
"participants": 3091,
"risk_difference": {
"value": 0.000017583757297257724,
"lower": -0.007081318114090713,
"upper": 0.007122879660006014
},
"group_1": "14 of 1,544",
"group_2": "14 of 1,547",
"difference": "0.0 points",
"interval": "-0.7 to 0.7",
"trial_title": "Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=125",
"request_id": "7k4kMM_rQmXgTEea"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant